Capital World Investors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Capital World Investors’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,470	Closed	-$15.4M	–	584
2022 Q1	$15.4M	Sell	12,470 -39	-0.3%	-$53.1K	﹤0.01%	505
2021 Q4	$31.6M	Sell	12,509 -4,926	-28%	-$30.1M	0.01%	495
2021 Q3	$320M	Buy	17,435 +798	+5%	+$12.7M	0.05%	257
2021 Q2	$176M	Buy	16,637 +12	+0.1%	+$101K	0.03%	324
2021 Q1	$120M	Buy	16,625 +3,574	+27%	+$25.7M	0.02%	345
2020 Q4	$72.5M	Buy	13,051 +24	+0.2%	+$213K	0.01%	374
2020 Q3	$130M	Hold	13,027	–	–	0.03%	310
2020 Q2	$121M	Buy	13,027 +9,310	+250%	+$85.3M	0.03%	292
2020 Q1	$33.9M	Buy	3,717 +855	+30%	+$8.44M	0.01%	358
2019 Q4	$32.1M	Buy	2,862 +1,570	+122%	+$9.47M	0.01%	382
2019 Q3	$6.44M	Buy	+1,292	New	+$7.95M	﹤0.01%	487

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Capital World Investors's IRLA Position: Q2 2022 in Review

Capital World Investors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 12,470 shares — an estimated $15.4M sold.

Capital World Investors first reported a position in IRLA in Q3 2019 and held it in 11 quarters. The position peaked at $320M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Capital World Investors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Capital World Investors sold 12,470 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $15.4M.
Capital World Investors first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2019 and held it in 11 quarters.
Capital World Investors's IRulya Therapeutics Inc. Common Stock position peaked at $320M in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Capital World Investors's 13F filing for Q2 2022, filed 15 Aug 2022.